Tezacaftor

URI: https://gptkb.org/entity/Tezacaftor

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:chemical_compound gptkb:drug
gptkbp:approvalYear	2018
gptkbp:approvedBy	gptkb:FDA gptkb:EMA
gptkbp:ATCCode	gptkb:R07AX31
gptkbp:brand	gptkb:Symkevi gptkb:Symdeko
gptkbp:CASNumber	gptkb:1226285-08-7
gptkbp:combines	gptkb:Ivacaftor
gptkbp:developedBy	gptkb:Vertex_Pharmaceuticals
gptkbp:eliminationHalfLife	18 hours
gptkbp:excretion	urine feces
gptkbp:hasMolecularFormula	gptkb:C26H28F2N2O7
https://www.w3.org/2000/01/rdf-schema#label	Tezacaftor
gptkbp:IUPACName	3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]oxy-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyridine-2-carboxylic acid methyl ester
gptkbp:legalStatus	prescription only
gptkbp:mechanismOfAction	CFTR corrector
gptkbp:metabolism	liver (CYP3A4, CYP3A5)
gptkbp:pregnancyCategory	B1 (Australia) N (US)
gptkbp:proteinBinding	99%
gptkbp:PubChem_CID	gptkb:CHEMBL3989989 DB14066 71587765
gptkbp:routeOfAdministration	oral
gptkbp:sideEffect	nausea dizziness headache sinus congestion
gptkbp:UNII	6X9OC3H4II
gptkbp:usedFor	cystic fibrosis
gptkbp:bfsParent	gptkb:CFTR
gptkbp:bfsLayer	7